Mode
Text Size
Log in / Sign up
N/A N=80 Randomized Double-blind Treatment

Comparison of the Efficacy of Two Different Suprascapular Nerve Block Techniques in Patients With Chronic Shoulder Pain

Chronic Shoulder Pain

Enrolled (actual)
80
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Change of Shoulder Pain and Disability Index (SPADI) — 22.1; 25.9; 27.0; 36.6 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
TC Erciyes University
Primary completion
Aug 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Change of Shoulder Pain and Disability Index (SPADI)
22.1; 25.9; 27.0; 36.6; 29.4; 34.1
SECONDARY
Change of Visual Analog Scale (VAS)
2.2; 2.8; 2.8; 3.7; 2.9; 3.5
SECONDARY
Change of Range of Motion (ROM)
-3.9; -9.6; -8.6; -18.6; -8.8; -20.5
SECONDARY
Change of Pain Pressure Threshold (PPT)
-0.3; 0.0; -0.1; -0.4; -0.2; -0.3
SECONDARY
Patient Satisfaction
3; 2; 8; 1; 3; 6

Summary

The aim of this study is to compare the efficacy and safety of the suprascapular nerve block (SSNB) at the spinoglenoid notch with SSNB at the suprascapular notch, which is the most commonly used technique in patients with chronic shoulder pain.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years old
  • Shoulder pain that last more than 3 month
  • Patients with a VAS value of ≥ 4 despite treatment (drugs used for analgesia, local injections and physiotherapy methods)
  • Shoulder pain defined as non-specific shoulder pain, subacromial impingement syndrome, rotator cuff tendinopathy, adhesive capsulitis, non-traumatic instability, SLAP lesion, acromioclavicular pathology, and / or shoulder osteoarthritis.

Exclusion Criteria

  • A history of uncontrolled chronic diseases, e.g., malignant neoplasms, blood dyscrasia, and infection
  • Previous surgery history at the affected shoulder
  • Shoulder injection in the last 3 months before treatment
  • The presence of cervical radiculopathy or myelopathy
  • A previous fracture close to the shoulder region
  • Presence of septic arthritis or local infection in the affected shoulder
  • Presence of anaphylaxis against local anesthetics and / or corticosteroids
  • Presence of a cardiac pacemaker
  • Pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04938037). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search